Lead­ing a $60M launch round, RA Cap­i­tal backs an­oth­er 'toad ven­om' start­up

A year and a half af­ter div­ing head­first in­to the psy­che­del­ic col­lo­qui­al­ly known as “toad ven­om,” RA Cap­i­tal is back for more.

Lusaris Ther­a­peu­tics an­nounced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER